The 14th International Conference on Malignant Lymphoma (ICML) took place June 14-17, 2017, in Lugano, Switzerland.

High ORR with sequential regimen in CLL

Micrograph showing CLL
A sequential treatment regimen can produce a high overall response rate (ORR) in patients with treatment-naïve (TN) or relapsed/refractory (RR) chronic lymphocytic leukemia (CLL), results of the CLL2-BAG study suggest. Patients who received bendamustine followed by obinutuzumab and venetoclax achieved an ORR of 95%, and 87% of them were negative... [Read Article]

GAD-M produces high ORR in treatment-naïve ENKTL

14th International Conference
on Malignant Lymphoma
A 4-drug regimen has demonstrated efficacy in a phase 2 trial of patients with treatment-naïve extranodal natural killer/T-cell lymphoma (ENKTL). Treatment with gemcitabine, PEG-asparaginase, dexamethasone, and methotrexate (GAD-M) produced a 94% overall response rate (ORR) and an 83% complete response (CR) rate in this trial. Responses and... [Read Article]

CTL019 produces responses in rel/ref DLBCL

Gilles Salles, MD, PhD
The chimeric antigen receptor (CAR) T-cell therapy CTL019 produced a high response rate in a phase 2 trial of adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to researchers. An interim analysis of the JULIET trial revealed a 3-month overall response rate (ORR) of 45%. Thirty-seven percent of... [Read Article]

Combo demonstrates activity in CLL/SLL and FL

Micrograph showing CLL
Results of a phase 1 study suggest a 2-drug combination may be safe and effective in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and follicular lymphoma (FL). The ongoing study is a test of the BTK inhibitor BGB-3111 and the anti-CD20 antibody obinutuzumab. The overall response rate... [Read Article]

Nivolumab for long-term treatment of cHL after auto-HSCT

Micrograph showing HL
Nivolumab can provide long-term treatment for a broad range of adults who have relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous hematopoietic stem cell transplant (auto-HSCT), according to a presentation at the 14th International Conference on Malignant Lymphoma (ICML). In the phase 2 CheckMate-205 study, cHL patients achieved... [Read Article]

CAR T-cell therapy shows early promise in DLBCL

Diffuse large B-cell lymphoma
The chimeric antigen receptor (CAR) T-cell therapy JCAR017 can produce “potent and durable” responses in patients with relapsed/refractory, aggressive diffuse large B-cell lymphoma (DLBCL), according to an investigator from the TRANSCEND trial. In this phase 1 trial, JCAR017, given after lymphodepleting chemotherapy, produced an overall response rate (ORR) of... [Read Article]

Chemo-free triplet produces ‘favorable’ results in advanced disease

Mantle cell lymphoma
A chemotherapy-free combination regimen has demonstrated “favorable” safety and efficacy in patients with advanced chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and non-Hodgkin lymphoma (NHL), according to researchers. They found that treatment with ublituximab, umbralisib, and ibrutinib produced responses in patients with CLL/SLL, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL),... [Read Article]

Inhibitor elicits responses in heavily pretreated FL, DLBCL

14th International Conference
 on Malignant Lymphoma (ICML)
Interim results of a phase 2 trial suggest tazemetostat can be effective in patients with heavily pretreated, relapsed or refractory non-Hodgkin lymphoma. The EZH2 inhibitor produced the highest overall response rate in patients with EZH2-mutated follicular lymphoma (FL), followed by EZH2-mutated diffuse large B-cell lymphoma (DLBCL). However, the... [Read Article]